Biotech
Israeli mathematician uses AI to decode human immune system
How an Israeli mathematician is using AI to decode the human immune system and transform patient treatment
Israel's overlooked challenge: Environmental damage from two years of war - from the editor
Immunai, Bristol Myers Squibb sign AI immune-data collaboration
Israeli researchers develop SafeWax coating that could cut pesticide use by 50%
Arkin raises $100m for early-stage biotech fund
The main investors in Arkin Bio Ventures III together with Arkin Capital are Israeli institutional investors including Phoenix Finance, Clal Insurance, and Amitim pension fund
Israel's biotech moment: How science, data, and geopolitics are converging - opinion
Why now Is the time to invest in a deeply built, undervalued market
EU Council and Parliament reach agreement to overhaul drug rules, speed patient access
The agreement grants companies launching new medicines eight years of data protection for trial results and one year of market protection.
Midlife weight loss shows metabolic benefits but sparks brain inflammation in BGU - study
“Our findings show that losing weight in midlife is not a simple copy-and-paste of what works in young adulthood,” Alon Zemer said.
Biotech between worlds: Jacob Licht's aliyah story - interview
A better question might be: For a couple who fell in love with Israel as teenagers, why did it take us so long to make aliyah?
Israeli woman's vision restored in world's first-ever 3D-printed cornea implant
The new Israeli technology allows for the creation of hundreds of cornea implants from a single donor sample, offering a scalable solution.
Jerusalem surges ahead: Aspiring to become Israel’s biotech capital
Jerusalem's biotech sector grows with $1.7B in investments and 150 companies. In June, the city will host the international medical hackathon MinDstart.
Jerusalem as our biotech capital: The city’s ascent as an innovation hub - opinion
Jerusalem's transformation is the outcome of long-term strategic policy, targeted public investment, and a thriving academic ecosystem.
Is former truck mechanic Tim Friede may be key in creating anti-venom biotech
Friede's subjected himself to over 200 snake bites.
Former Pfizer R&D chief Mikael Dolsten joins Immunai’s board of directors
Dolsten brings decades of pharmaceutical leadership to advance AI-driven drug discovery.
